#ICER found sotatercept would likely improve #PAH, but had efficacy concerns in more severe disease & lack of long-term data. ICER estimated an annual price at $18k-$35k/year. Merck set WAC at $238k/year @prescriberight#pharmacists#physicians#nurses https://t.co/VRfUpc8Z2U
#FDAapproved $MRK #newdrug#sotatercept to treat #PAH, based on the 24-week, 323 patient, Phase III, STELLAR trial, where patients treated with sotatercept improved their 6-min walk distance by 34.4 meters compared to 1 meter with placebo https://t.co/VRfUpc8Z2U
The FDA declined early approval of $REGN odronextamab in March 2024 and requested that confirmatory portions of two pivotal trials be underway before approval can be considered. @prescriberight#newdrug#pharmacists#physicians#nurses https://t.co/z1m9eGBkxe
#FDAapproved $ORTX #newdrug atidarsagene autotemcel gene therapy for metachromatic leukodystrophy. #ICER found a strong health benefit in pre-symptomatic & moderate benefit in early symptomatic MLD & est price of $2.3-$3.9 million. @prescriberight#pharmacists#physicians#nurses